#1signifyhealth. Third Quarter 2021 Earnings Summary November 10, 2021 Homeward.#2Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. These statements may be preceded by, followed by or include the words "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business, our ability to realize synergies in our businesses, our 2021 Outlook, including our 2021 estimates for total GAAP revenue, total Adjusted EBITDA, in-home evaluations, program size and weighted average savings rate, our ability to continue to gain traction in our Transition to Home solution, and our ability to grow our non-BPCI-A episodes of care business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include: the COVID-19 pandemic and whether the pandemic will continue to subside in 2021; our dependence upon a limited number of key customers; our dependence on certain key government programs; our failure to maintain and grow our network of high-quality providers; our failure to continue to innovate and provide services that are useful to customers and achieve and maintain market acceptance; our limited operating history with certain of our solutions; our failure to compete effectively; the length and unpredictability of our sales cycle; failure of our existing customers to continue or renew their contracts with us; failure of service providers to meet their obligations to us; seasonality that may cause fluctuations in our sales, cash flows and results of operations; our failure to achieve or maintain profitability; our revenues not growing at the rates they historically have, or at all; our failure to successfully execute on our growth initiatives, business strategies, or operating plans, including growth in our non-BPCI-A episodes of care business; our failure to successfully launch new products; our failure to diversify sources of revenues and earnings; inaccurate estimates and assumptions used to determine the size of our total addressable market; changes in accounting principles applicable to us; incorrect estimates or judgments relating to our critical accounting policies; our failure to effectively adapt to changes in the healthcare industry, including changes in the rules and regulations governing Medicare or other federal healthcare programs or a potential shift toward total cost of care payment models; our failure to adhere to complex and evolving governmental laws and regulations; our failure to comply with current and future federal and state privacy, security and data protection laws, regulations or standards; our employment of and contractual relationships with our providers subjecting us to licensing or other regulatory risks, including recharacterization of our contracted providers as employees; adverse findings from inspections, reviews, audits and investigations from health plans and governmental agencies; inadequate investment in or maintenance of our operating platform and other information technology and business systems; our ability to develop and/or enhance information technology systems and platforms to meet our changing customer needs; higher than expected investments in our business including, but not limited to, investments in our technology and operating platform, which could reduce our profitability; security breaches or incidents, loss or misuse of data, a failure in or breach of our operational or security systems or other disruptions; disruptions in our disaster recovery systems or management continuity planning; our ability to comply with, and changes to, laws, regulations and standards relating to privacy or data protection; our ability to obtain, maintain, protect and enforce our intellectual property; our dependence on distributions from Cure TopCo, LLC, our operating subsidiary, to fund dividend payments, if any, and to pay our taxes and expenses, including payments under our Tax Receivable Agreement; the control certain equity holders have over us and our status as a controlled company; our ability to realize any benefit from our organizational structure; risks associated with acquiring other businesses, including our ability to effectively integrate the operations and technologies of the acquired businesses; risks associated with an increase in our indebtedness; and the other risk factors described under "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which are available free of charge on the SEC's website at: www.sec.gov All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required under the federal securities laws. This presentation contains certain financial measures not presented in accordance with generally accepted accounting principles in the United State ("GAAP"), including Adjusted EBITDA, which is used by management in making operating decisions, allocating financial resources, and internal planning and forecasting and for business strategy purposes. Adjusted EBITDA is not a measure of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, this measure should not be considered in isolation or as an alternative to GAAP measures. Our presentation of Adjusted EBITDA may not be comparable to similarly-titled measures used by other companies. Management believes that such measures are commonly reported by issuers and widely used by investors as indicators of a company's operating performance. There are other non-GAAP financial measures which should be considered only as a supplement to, and not as a superior measure to, financial measures prepared in accordance with GAAP. Please refer to the Appendix of this document for a reconciliation of Adjusted EBITDA to the most directly comparable financial measure prepared in accordance with GAAP. This presentation includes market and industry data and forecasts that we have derived from independent consultant reports, publicly available information, various industry publications, other published industry sources, and our internal data and estimates. Independent consultant reports, industry publications, and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. The inclusion of market estimations, rankings, and industry data in this presentation is based upon such reports, publications, and other sources and our internal data and estimates and our understanding of industry conditions. Although we believe that such information is reliable, we have not had this information verified by any independent sources. You are cautioned not to give undue weight to such estimates. All trademarks, service marks, and trade names appearing in this presentation are the property of their respective holders. signifyhealth. 2#3--> Q3 2021 highlights Total Operations Revenue ● ● ● ● Home & Community Services ● Net Income Adjusted EBITDA (1) Adjusted EBITDA Margin (¹) Revenue Adjusted EBITDA (1) Episodes of Care Services ● Revenue Adjusted EBITDA (1) signifyhealth $199.2M $ 29.3M $ 42.0M 21.1% $169.1M $ 49.9M $30.1M ($7.9) M ● ● 29% increase in revenue driven by strong HCS results Strong operating performance and $27.3M EAR revaluation 46% increase in adjusted EBITDA driven by HCS revenue 250 basis point increase in adjusted EBITDA Margin 47% increase in revenue and 139% increase in adjusted EBITDA due to strong in-home-evaluation volume of ~488K compared to -362K in Q3 2020 1.447 million 9 mos 2021 IHE volume exceeds 2020 total year volume 25% reduction in revenue reflects adverse COVID-19 impact on program size, and in 2020 there was an increase in estimated revenue of $9.2M related to positive new information ahead of 4Q 2020 BPCI-A reconciliation Next BPCI-A reconciliation expected in 4Q 2021 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin 3#4Signify Health Total --> 3rd Quarter Results September 30, 2021 Total Revenue ($ in millions) signifyhealth. $155 Q3 2020 +29% $199 Q3 2021 Total Adj. EBITDA(¹) ($ in millions) $29 Q3 2020 +46% 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin $42 Q3 2021 4#5Signify Health Total Nine Month Results through September 30, 2021 Total Revenue ($ in millions) signifyhealth. $417 9 mos 2020 + 42% $592 9 mos 2021 Total Adj. EBITDA(¹) ($ in millions) $86 9 mos 2020 +52% 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin $131 9 mos 2021 5 |#62021 Full Year Guidance Progression Initial Guidance Mar 2021 $725-760M Revenue Adjusted EBITDA (1) IHE Volume ECS Program Size signifyhealth $150-160M $150-160M 1.7-1.75M $5.1-5.3B 1Q May 2021 $725-760M 7.5-7.8% 1.7-1.75M $5.1-5.3B 7.5-7.8% 2Q Aug 2021 $745-765M $155-165M $4.9-5.1B 3Q Nov 2021 $755-770M 1.785-1.815M 1.815-1.855M 6.1%-6.4% $160-170M $4.9-5.1B 6.1%-6.4% Drivers HCS growth due to strong customer demand for IHES Savings Rate 1) We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense, depreciation and amortization and certain items of income and expense, including asset impairment, other (income) expense, net transactions-related expenses, equity-based compensation, remeasurement of contingent consideration, customer equity appreciation rights, SEU expense, loss on extinguishment of debt, and non-recurring expenses. See slide titled "Reconciliation from GAAP net loss to Adjusted EBITDA" for a reconciliation of Adjusted EBITDA to net loss and the calculation of Adjusted EBITDA Margin COVID-19 impact 6#7→> Drivers of future performance ● ● ● Projected ECS program size at the end of 2021-$6 billion exit run rate • ECS savings rate ● ● Strong customer IHE demand in Home and Community Services In-home service expansion: ● > Additional diagnostic testing services Medication management ► Chronic condition management Remote patient monitoring Expansion of synergistic Transition to Home services Investments in non-BPCI-A Episodes of Care Services to drive chronic condition episode adoption and network expansion Possible acquisitions to add functionality and innovation to our platform signifyhealth. 7#8Appendix signifyhealth. 8 [#9--> Reconciliation from GAAP Net (Loss) Income to Adjusted EBITDA $ in millions signifyhealth. Net (loss) income Interest expense Loss on extinguishment of debt Income tax expense (benefit) Depreciation and amortization Other expense (income), net Asset impairment Equity-based compensation Customer equity appreciation rights Transaction-related expenses SEU expense Other(1) Adjusted EBITDA Adjusted EBITDA Margin 9 Months Ended September 30 2021 (22.5) 17.5 5.0 (3.7) 51.6 43.6 9.5 14.8 9.5 2.0 3.7 131.0 22.1% 2020 (15.2) 16.2 -- 0.5 46.0 6.9 -- 10.0 7.5 10.8 -- 3.3 86.0 20.6% 3 Months September 30 2021 29.3 4.2 6.4 17.6 (27.4) 3.7 5.0 2.9 0.2 0.1 42.0 21.1% 2020 (13.3) 5.1 0.2 15.8 6.3 2.1 4.9 6.8 -- 0.8 28.7 18.6% 1) Other includes remeasurement of contingent consideration, non-recurring expenses, including those associated with one-time costs related to the COVID-19 pandemic, the closure of certain facilities, the sale of certain assets and the early termination of certain contracts. 9